Brief: Bioxcel Therapeutics Says Deal With Teva Includes $57.5 Mln Cash, Up To $67.5 Mln Development Milestones
28/08/2026 11:12
BRIEF-Bioxcel Therapeutics Says Deal With Teva Includes $57.5 Mln Cash, Up To $67.5 Mln Development Milestones Aug 28 (Reuters) - BioXcel Therapeutics Inc BTAI.O:
BIOXCEL THERAPEUTICS - DEAL WITH TEVA INCLUDES $57.5 MILLION CASH, UP TO $67.5 MILLION DEVELOPMENT MILESTONES, $20 MILLION COMMERCIAL MILESTONES - SEC FILING
Source text: [ID:n0001104659-26-102570]
Further company coverage: BTAI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on BioXcel Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Bleichroeder Acquisition Corp, Halliburton, BioNTech
U.S. STOCKS ON THE MOVE-Halliburton, BioNTech, Kazia Therapeutics
U.S. STOCKS ON THE MOVE-Cytokinetics, Moderna
Brief: Bioxcel Therapeutics Enters Into Asset Sale Agreement With Teva Pharmaceuticals
U.S. STOCKS ON THE MOVE-Cytokinetics, Moderna, Ulta Beauty